Skip to content
MS
Sign in
unreviewed

Adenosine deaminase (ADA)

1 reactions · 1 pathways

Cofactors used

H2O

Clinical / pharmacological. ADA deficiency: severe combined immunodeficiency (dATP accumulation inhibits RNR)

What it does, reaction by reaction

1 reactions

Purine Degradation (to Uric Acid) Nucleotide Metabolism · Cytosol

step 3 Irreversible/directional

Adenosine → inosine

Converts Adenosine into Inosine

› Notes

Adenosine deaminase (ADA) catalyzes adenosine + H2O → inosine + NH3. The enzyme requires no external redox cofactor and channels adenosine toward hypoxanthine production.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Purine Degradation (to Uric Acid)

Listed there as: Adenosine deaminase

Accelerated by

Adenosine availability

Inhibited by

No major physiologic small-molecule allosteric inhibitor

Hormonal control

No established direct hormonal regulation.

Recent literature

Refresh

Europe PMC · from cache · sorted by publication date

  1. 1
    Clinical immunogenicity and pharmacokinetic assessments of E3112, a recombinant human hepatocyte growth factor.

    Aoyama M, Takanohashi T, Ohba F, Mano Y. · 2026-07-04

    unreviewed
  2. 2
    Overexpression of LINC00472 alleviates diabetic kidney disease progression via the miR-21-5p/STAT3 axis.

    Sun P, Hu Y, Xu Z, Xiong F. · 2026-06-09

    open access unreviewed
  3. 3
    Generation of human sequence antibodies in OmniChicken against the highly conserved mammalian target BDNF using three distinct discovery workflows.

    Ching KH, Keating S, Zeng B, Espinosa DA, Stack E, Wall S, Beyer S, Wade J, Tam A, Cunningham O, Chowdhury R,… · 2026-06-04

    open access unreviewed
  4. 4
    Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.

    Park MJ, Han JK, Lam KK. · 2026-06-03

    open access unreviewed
  5. 5
    Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.

    Mao H, Zhang Y, Liu M, Yao Y, Peng Y, Zhou X, Huang H, Fei W, Zheng C, Ye Y. · 2026-05-27

    open access unreviewed
  6. 6
    Could AAV-vectored delivery of broadly neutralizing antibodies (bNAbs) reduce virologic failure in children diagnosed with perinatal HIV?

    Pringle KL, Martins MA. · 2026-05-22

    open access unreviewed
  7. 7
    Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.

    van Lier D, Genest M, Picod A, Manicone F, Garcia B, Uba TI, Schroeter A, Santos K, Herpain A, Nguyen A, Azib… · 2026-05-21

    cited 1× open access unreviewed
  8. 8
    Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.

    van Lier D, Mourisse L, Hollander H, Santos K, Bergmann A, van Herwaarden AE, Kox M, Pickkers P. · 2026-05-21

    cited 1× open access unreviewed
  9. 9
    Interplay between vaccine-related informational milestones, social media discourse, and vaccine administration rates for human papillomavirus and measles/mumps/rubella vaccines in the United States.

    Annan A, Wang D, Du J, Nomula VK, Rastegar-Mojarad M, Frew PM, Eiden AL. · 2026-05-11

    open access unreviewed
  10. 10
    A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human.

    Gajewska M, Kiffe M, Calonder C, Engelhardt V, Pou I Miralbell C, Gonzalo-Gil E, Christianson G, Bethur N, Fl… · 2026-05-07

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.